Terms: = Ovarian cancer AND TFRC, P02786, 7037, ENSG00000072274, TFR1, CD71
17 results:
1. Long term pregnancy outcomes of women with cancer following fertility preservation: A systematic review and meta-analysis.
Xu Z; Ibrahim S; Burdett S; Rydzewska L; Al Wattar BH; Davies MC
Eur J Obstet Gynecol Reprod Biol; 2023 Feb; 281():41-48. PubMed ID: 36535069
[TBL] [Abstract] [Full Text] [Related]
2. Preferential uptake of antibody targeted calcium phosphosilicate nanoparticles by metastatic triple negative breast cancer cells in co-cultures of human metastatic breast cancer cells plus bone osteoblasts.
Bussard KM; Gigliotti CM; Adair BM; Snyder JM; Gigliotti NT; Loc WS; Wilczynski ZR; Liu ZK; Meisel K; Zemanek C; Mastro AM; Shupp AB; McGovern C; Matters GL; Adair JH
Nanomedicine; 2021 Jun; 34():102383. PubMed ID: 33722692
[TBL] [Abstract] [Full Text] [Related]
3. Efficient iron utilization compensates for loss of extracellular matrix of ovarian cancer spheroids.
Wang Q; Gu T; Ma L; Bu S; Zhou W; Mao G; Wang LL; Guo Y; Lai D
Free Radic Biol Med; 2021 Feb; 164():369-380. PubMed ID: 33450374
[TBL] [Abstract] [Full Text] [Related]
4. Protein Encapsulation of Experimental Anticancer Agents 5F 203 and Phortress: Towards Precision Drug Delivery.
Breen AF; Scurr D; Cassioli ML; Wells G; Thomas NR; Zhang J; Turyanska L; Bradshaw TD
Int J Nanomedicine; 2019; 14():9525-9534. PubMed ID: 31824148
[TBL] [Abstract] [Full Text] [Related]
5. Enhanced antitumor efficacy of cisplatin for treating ovarian cancer in vitro and in vivo via transferrin binding.
Peng H; Jin H; Zhuo H; Huang H
Oncotarget; 2017 Jul; 8(28):45597-45611. PubMed ID: 28484093
[TBL] [Abstract] [Full Text] [Related]
6. Iron addiction: a novel therapeutic target in ovarian cancer.
Basuli D; Tesfay L; Deng Z; Paul B; Yamamoto Y; Ning G; Xian W; McKeon F; Lynch M; Crum CP; Hegde P; Brewer M; Wang X; Miller LD; Dyment N; Torti FM; Torti SV
Oncogene; 2017 Jul; 36(29):4089-4099. PubMed ID: 28319068
[TBL] [Abstract] [Full Text] [Related]
7. Transferrin facilitates the formation of DNA double-strand breaks via transferrin receptor 1: the possible involvement of transferrin in carcinogenesis of high-grade serous ovarian cancer.
Shigeta S; Toyoshima M; Kitatani K; Ishibashi M; Usui T; Yaegashi N
Oncogene; 2016 Jul; 35(27):3577-86. PubMed ID: 26549031
[TBL] [Abstract] [Full Text] [Related]
8. Iron alters cell survival in a mitochondria-dependent pathway in ovarian cancer cells.
Bauckman K; Haller E; Taran N; Rockfield S; Ruiz-Rivera A; Nanjundan M
Biochem J; 2015 Mar; 466(2):401-13. PubMed ID: 25697096
[TBL] [Abstract] [Full Text] [Related]
9. Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.
Loisel S; André PA; Golay J; Buchegger F; Kadouche J; Cérutti M; Bologna L; Kosinski M; Viertl D; Delaloye AB; Berthou C; Mach JP; Boumsell L
Mol Cancer; 2011 Apr; 10():42. PubMed ID: 21504579
[TBL] [Abstract] [Full Text] [Related]
10. Systematic antigenic profiling of hematopoietic antigens on ovarian carcinoma cells identifies membrane proteins for targeted therapy development.
Helpman L; Katz BZ; Safra T; Schreiber L; Levine Z; Nemzer S; Kinar Y; Grisaru D
Am J Obstet Gynecol; 2009 Aug; 201(2):196.e1-7. PubMed ID: 19646570
[TBL] [Abstract] [Full Text] [Related]
11. Transferrin receptor 2 is frequently expressed in human cancer cell lines.
Calzolari A; Oliviero I; Deaglio S; Mariani G; Biffoni M; Sposi NM; Malavasi F; Peschle C; Testa U
Blood Cells Mol Dis; 2007; 39(1):82-91. PubMed ID: 17428703
[TBL] [Abstract] [Full Text] [Related]
12. Effect of a combination of extract from several plants on cell-mediated and humoral immunity of patients with advanced ovarian cancer.
Kormosh N; Laktionov K; Antoshechkina M
Phytother Res; 2006 May; 20(5):424-5. PubMed ID: 16619374
[TBL] [Abstract] [Full Text] [Related]
13. Hemochromatosis gene mutations and distal adenomatous colorectal polyps.
McGlynn KA; Sakoda LC; Hu Y; Schoen RE; Bresalier RS; Yeager M; Chanock S; Hayes RB; Buetow KH
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):158-63. PubMed ID: 15668490
[TBL] [Abstract] [Full Text] [Related]
14. Differences in the intracellular fate of free and polymer-bound doxorubicin.
Hovorka O; St'astný M; Etrych T; Subr V; Strohalm J; Ulbrich K; Ríhová B
J Control Release; 2002 Apr; 80(1-3):101-17. PubMed ID: 11943391
[TBL] [Abstract] [Full Text] [Related]
15. Ascitic fluid-associated lymphocytes in patients with metastatic ovarian cancer. Analysis of lymphocyte subsets and of phenotypical changes induced by "in vitro".
Loiudice L; Dell'Osso A; Loria MP; D'Ambra PP; Lasaracina E; Crollo E; Lucivero G
Eur J Gynaecol Oncol; 1995; 16(4):301-6. PubMed ID: 7556288
[TBL] [Abstract] [Full Text] [Related]
16. Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
Pearson JW; Fogler WE; Volker K; Riggs CW; Gruys E; Groves ES; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1993 Jun; 85(11):907-12. PubMed ID: 8492319
[TBL] [Abstract] [Full Text] [Related]
17. [Lymphocytic subpopulations in malignant ascites of ovarian origin. Flow cytometric analysis].
De Leonardis A; Casamassima A; Chiuri E; Addabbo L; De Frenza N; Falco G
Minerva Ginecol; 1993 Jun; 45(6):291-300. PubMed ID: 8355884
[TBL] [Abstract] [Full Text] [Related]
